Global Oncology Lecture Series on the African Access Initiative (AAI)


GLOBAL  ONCOLOGY  LECTURE  SERIES
Monday, August 28, Noon–1:00 PM
The African Access Initiative (AAI)

Jennifer Dent
President, BIO Ventures for Global Health (BVGH)

Learn about BVGH’s newest program – the African Access Initiative – and how BVGH is leveraging its relationships with pharmaceutical and biotechnology companies to improve cancer patient management and provide affordable, sustainable access to essential cancer technologies and medicines in Africa. Beyond providing access to the needed technologies and medicines, BVGH will strengthen healthcare infrastructure and build healthcare provider and cancer researcher capacity in four countries – Cameroon, Cote d’Ivoire, Kenya, and Nigeria.


Fred Hutchinson Cancer Research Center

1100 Fairview Ave. N., Arnold Building, Room M1-A307
(30 lunches provided)


For more information, please contact Michele Roe, mroe1@seattlecca.org
Map of the Fred Hutch Campus

 

Africa’s Emerging Cancer Crisis: A Call to Action

(June 28, 2017) – In partnership with the African Organisation for Research and Training in Cancer (AORTIC) and key oncology leaders, BVGH released a white paper on the African continent’s emerging cancer crisis. The publication discusses cancer as a growing public health threat in Africa, the lack of funding and limited access to quality care that underlie the cancer crisis, and a call to action through public-private partnerships. Click here to read more.

International Drug Companies Join BIO Ventures for Global Health to Tackle Cancer Crisis in Africa

(June 21, 2017) – BVGH is launching the African Access Initiative (AAI) at the Biotechnology Innovation Organization (BIO) International Convention in San Diego. AAI will expand access to oncology medicines and improve cancer care in Africa. Led by BVGH in partnership with Pfizer, Inc., Takeda Pharmaceutical Co., Ltd., and the African Organisation for Research and Training in Cancer (AORTIC), AAI will expand access to oncology medicines and improve cancer care in Africa. Click here to read more.

Breast Cancer More Aggressive, Deadlier in African Women than Caucasian Women

(June 20, 2017) –  Dr. Olufunmilayo (Funmi) Olopade, a native of Nigeria and founding director of the Center for Clinical Cancer Genetics at the University of Chicago, has dedicated her career to unraveling breast cancer biology in women of African descent. Her pioneering research, published in leading scientific journals, has shown that the disease “hits earlier and harder” in Africa than among Caucasian women in the United States. BVGH’s new African Access Initiative (AAI) will help address the cancer crisis and build the capacity and infrastructure needed to support further research on Africa’s cancer landscape and clinical trials of existing and new treatments. Dr. Olopade and Dr. Pol Vandenbroucke, Vice President of the Medical Strategy at Pfizer, will join BVGH’s Board of Directors to strengthen its expertise in oncology and healthcare delivery in Africa. Click here to read more.

BIO 2017: A Peek at Pavilions | Sub-Saharan Africa

(May 18, 2017) – The Biotechnology Innovation Organization (BIO) published an article highlighting the Africa Pavilion at the 2017 BIO International Convention as part of their Peek at Pavilions series. Learn about the Africa Pavilion exhibitors and the unique opportunity to “visit” 24 African countries at booth #243 at the BIO Convention in June. Click here to read more.

Cancer Crisis in Africa Prompts BVGH’s New African Access Initiative

(May 17, 2017) – In a press release today, BVGH announced that it will expand its programs to address the emerging cancer crisis in Africa. The African Access Initiative (AAI) will provide affordable, sustainable access to cancer therapeutics, enhance healthcare capacity, and foster cancer research in Africa. BVGH will launch its new initiative at the BIO International Convention in San Diego on June 21, 2017. Click here to read more.